Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2008-10-06 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Annual Report to Shareholders 72 pages ?Kb
Regulatory Filings
2008-10-06 English
Audited Financial Report 66 pages ?Kb
Regulatory Filings
2008-09-22 English
Preliminary Final Report 37 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Preliminary Final Report for the year ended 30 June, 2008' and includes detailed financial results, income statements, balance sheets, cash flow statements, and notes to the financial statements. It references Appendix 4E, which is a regulatory filing format used in Australia for preliminary final reports. The document contains substantive financial data and analysis for the full fiscal year ending June 30, 2008. It is not merely an announcement or a certification but a full financial report. Therefore, it fits the definition of an Annual Report (10-K equivalent). The length of the document (15,000 characters) and the presence of detailed financial statements confirm it is the report itself, not just an announcement or summary. FY 2008
2008-08-28 English
Appendix 4C - quarterly 7 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Living Cell Technologies Announces Appendix 4C Quarterly Report' and contains detailed financial data for the quarter ended June 30, 2008. It includes a consolidated statement of cash flows, cash reconciliation, payments to directors, and compliance statements. The Appendix 4C is a recognized quarterly report format for entities admitted on the basis of commitments, commonly used in Australian regulatory filings to report quarterly cash flows and financing activities. The document is comprehensive, with actual financial data and analysis for the quarter, not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2008
2008-07-30 English
LCT Expands Management Team 2 pages ?Kb
Board/Management Information Classification · 95% confidence The document is a company announcement from Living Cell Technologies Ltd dated July 29, 2008. It announces the expansion of the management team and the appointment of Dr. Robert Caspari as CEO. The content focuses on management changes, detailing the background of the new CEO and the company's strategic direction. There are no financial statements, regulatory filings, or detailed financial data presented. The document is not a report or presentation but an announcement of a management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is sufficient to contain substantive information about the management change, not just a brief notice, supporting this classification with high confidence.
2008-07-28 English
Change of Director`s Interest Notice 3 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about changes in a director's relevant interests in securities, including the number of shares held before and after the change, dates, and nature of the transactions. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director share transactions. The content is specific to personal share transactions by a company director, which aligns with the definition of Director's Dealing filings. The document length is 3602 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the correct classification is Director's Dealing (DIRS).
2008-07-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.